Want to see JP:4967 full AI Analyst Report?
4967 Stock Chart & Stats
¥5473.00
¥142.00(2.59%)
At close: 4:00 PM EDT
¥5473.00
¥142.00(2.59%)
Day’s Range― - ―
52-Week Range¥5,030.00 - ¥6,140.00
Previous CloseN/A
Volume130.40K
Average Volume (3M)221.72K
Market Cap
¥414.42B
Enterprise Value¥348.55K
Total Cash (Recent Filing)¥65.03B
Total Debt (Recent Filing)¥727.00M
Price to Earnings (P/E)135.4
Beta0.33
Next Earnings
Nov 05, 2026EPS Estimate
48.43Next Dividend Ex-DateN/A
Dividend Yield1.88%
Share Statistics
EPS (TTM)41.28
Shares Outstanding78,050,000
10 Day Avg. Volume218,190
30 Day Avg. Volume221,720
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.91
Price to Sales (P/S)2.43
P/FCF Ratio32.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)140.07
Revenue Forecast (FY)¥172.65B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low debt and sizable equity (~¥205–213B vs total assets) provide durable financial resilience, preserving flexibility to fund operations, absorb shocks, and pursue selective investments or buybacks without relying on leverage, supporting stability over the next months.
Recovering Cash GenerationA pronounced rebound in operating and free cash flow in 2025 improves the firm’s ability to fund capex, marketing, and dividends from operations rather than financing. If sustained, the improved cash conversion strengthens long-term operational flexibility and strategic execution.
Resilient Consumer Staples ModelCore business of branded OTC, personal care, and household consumables relies on repeat purchases, broad retail distribution and brand-driven pricing. This structural demand and scale in manufacturing/distribution underpin predictable revenue streams and defendable market share over 2–6 months.
Bears Say
Earnings DeclineA steep multi-year drop in net income indicates persistent margin pressure or cost/headwind issues that erode the company’s ability to generate returns. Continued weaker profitability reduces reinvestment capacity and risks further declines in ROE and shareholder distributions.
Volatile Cash ConversionLarge swings in free cash flow point to working-capital or extraordinary outflows that impair predictable cash generation. That volatility complicates planning for investment, dividends, and debt service and raises the risk that recovery may reverse under stress.
Stagnant Top-line GrowthLow single-digit revenue growth and flat sales restrict operating leverage and limit margin expansion. Without meaningful new product success or market expansion, sustaining past profitability levels will be difficult and long-term growth upside appears constrained.
Kobayashi Pharmaceutical Co News
4967 FAQ
What was Kobayashi Pharmaceutical Co Ltd’s price range in the past 12 months?
Kobayashi Pharmaceutical Co Ltd lowest stock price was ¥5030.00 and its highest was ¥6140.00 in the past 12 months.
What is Kobayashi Pharmaceutical Co Ltd’s market cap?
Kobayashi Pharmaceutical Co Ltd’s market cap is ¥414.42B.
When is Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date?
Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 87 days.
How were Kobayashi Pharmaceutical Co Ltd’s earnings last quarter?
Kobayashi Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported ¥1.34 earnings per share for the quarter, missing the consensus estimate of ¥24.21 by -¥22.87.
Is Kobayashi Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kobayashi Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Kobayashi Pharmaceutical Co Ltd pay dividends?
Kobayashi Pharmaceutical Co Ltd pays a Semiannually dividend of ¥61 which represents an annual dividend yield of 1.88%. See more information on Kobayashi Pharmaceutical Co Ltd dividends here
What is Kobayashi Pharmaceutical Co Ltd’s EPS estimate?
Kobayashi Pharmaceutical Co Ltd’s EPS estimate is 48.43.
How many shares outstanding does Kobayashi Pharmaceutical Co Ltd have?
Kobayashi Pharmaceutical Co Ltd has 78,050,000 shares outstanding.
What happened to Kobayashi Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kobayashi Pharmaceutical Co Ltd reported an EPS of ¥1.34 in its last earnings report, missing expectations of ¥24.21. Following the earnings report the stock price went up 1.961%.
Which hedge fund is a major shareholder of Kobayashi Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4967
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kobayashi Pharmaceutical Co Ltd
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.